A Phase 2 interventional study of Ranolazine and Placebo in Diabetes Mellitus, Type 2, sponsored by Gilead Sciences. Completed at 9 sites in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2013-09-23.
Sponsored by Gilead Sciences · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies testing ranolazine in Diabetes Mellitus, Type 2 — none open to participants now, none under way, none of them phase 3. Ranolazine · Diabetes Mellitus, Type 2.
Among the 11 studies testing ranolazine in Diabetes Mellitus, Type 2, this one is the 5th largest by enrollment, is the only one that started in 2010, is the only one in phase 2, and was the 1st registered.
10,382 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →None of the 11 studies testing ranolazine in Diabetes Mellitus, Type 2 is open now. The open studies under Diabetes Mellitus, Type 2, anywhere →
Ranolazine: first FDA approval 2006 (RANEXA), first EMA approval 2008. What it is approved for, and how studies give it, is on its page →
Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
First in 2010; this study’s year is marked. 1 started in 2010.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 80 is close to the median of 80 across 8,361 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 47 across the 11 interventional studies. Of the 9 that completed or were terminated, 6 (67%) have results posted.
This tab as a report to print or save as PDF → With an account.
9 of 11 have an industry lead sponsor. The 3 most frequent:
Gilead Sciences is the lead sponsor of 692 studies on the registry; 26 are open to participants now.
Of its 261 completed or terminated interventional studies of FDA-regulated products, 251 (96%) have results posted.
12 studies in Diabetes Mellitus, Type 2 by Gilead Sciences: none open now, none under way, none of them phase 3. Of 11 finished, 5 (45%) have results posted.
Among the 12 studies in Diabetes Mellitus, Type 2 by Gilead Sciences, this one is the 7th largest by enrollment, is the only one that started in 2010, is one of 3 in phase 2, and was the 4th registered.
Gilead Sciences’s Diabetes Mellitus, Type 2 studies by the year they started, since 2006.
None of the studies under way reaches primary completion within a year.
Among the 11 studies testing ranolazine in Diabetes Mellitus, Type 2, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Gilead Sciences’s 12 in Diabetes Mellitus, Type 2:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study enrolled participants with inadequately controlled type 2 diabetes mellitus (T2DM) despite non-insulin antidiabetic therapy in addition to diet and exercise, and would have benefited from additional control of blood glucose levels. The study assessed the metabolic effects of ranolazine, including its effect in lowering glycosylated hemoglobin A1c (HbA1c), and lowering glucose while fasting, and following a meal (postprandial).
Participants were randomized in a 1:1 ratio to receive ranolazine or placebo, and were stratified by HbA1c ≤ 7.5% or > 7.5%. Enrollment was to include no more than two-thirds of participants with baseline HbA1c ≤ 7.5%. Other than glucose values, efficacy endpoint results remained blinded during the study; for safety purposes, the investigator was to be alerted of severe hyperglycemia or hypoglycemia.
Participants were instructed to maintain logs of their physical activity/exercise (Subject Activity Assessment) and study drug dosing (Dosing Log).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants were randomized to receive ranolazine for 12 weeks.
Drug: Ranolazine
Participants were randomized to receive placebo to match ranolazine for 12 weeks.
Drug: Placebo
Ranolazine ER 1000 mg (two 500 mg tablets) administered orally twice daily
Also known as: Ranexa®
Placebo to match ranolazine administered orally twice daily
Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 12
HbA1c is a blood test to measure blood sugar control over the prior 3-month period. The last observation carried forward (LOCF) method was used: the last observed post-baseline measurements prior to Week 12 carried forward for participants with no available Week 12 values. Participants were summarized according to the actual treatment received regardless of the allocated treatment.
Time frame: Baseline to Week 12
Change From Baseline in 2-hour Postprandial Serum Glucose at Week 12 Following a Standardized Meal
2-hour postprandial serum glucose was defined as the average of serum glucose measurement at 120 minutes and 125 minutes following a standardized meal. The LOCF method was used. Participants were summarized according to the actual treatment received regardless of the allocated treatment.
Time frame: Baseline to Week 12
Change From Baseline in Fasting Serum Glucose at Week 12
Serum glucose was measured following an overnight fast. The LOCF method was used. Participants were summarized according to the actual treatment received regardless of the allocated treatment.
Time frame: Baseline to Week 12
Participants with type 2 diabetes mellitus (T2DM) were enrolled in a total of 9 study sites in the United States. The first participant was screened on 22 June 2010. The last participant observation was on 15 November 2010.
| Milestone | Ranolazine | Placebo |
|---|---|---|
| Started | 39 | 41 |
| Completed | 31 | 29 |
| Not completed | 8 | 12 |
| Withdrew: Adverse event | 5 | 6 |
| Withdrew: Withdrawal by subject | 3 | 4 |
| Withdrew: Lost to follow-up | 0 | 1 |
| Withdrew: Physician decision | 0 | 1 |
HbA1c is a blood test to measure blood sugar control over the prior 3-month period. The last observation carried forward (LOCF) method was used: the last observed post-baseline measurements prior to Week 12 carried forward for participants with no available Week 12 values. Participants were summarized according to the actual treatment received regardless of the allocated treatment.
| percent of HbA1c in blood | Ranolazine | Placebo |
|---|---|---|
| Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 12 | -0.61 ± 0.142 | -0.08 ± 0.142 |
2-hour postprandial serum glucose was defined as the average of serum glucose measurement at 120 minutes and 125 minutes following a standardized meal. The LOCF method was used. Participants were summarized according to the actual treatment received regardless of the allocated treatment.
| mg/dL | Ranolazine | Placebo |
|---|---|---|
| Change From Baseline in 2-hour Postprandial Serum Glucose at Week 12 Following a Standardized Meal | -26.6 ± 9.88 | -11.2 ± 9.63 |
Serum glucose was measured following an overnight fast. The LOCF method was used. Participants were summarized according to the actual treatment received regardless of the allocated treatment.
| mg/dL | Ranolazine | Placebo |
|---|---|---|
| Change From Baseline in Fasting Serum Glucose at Week 12 | 2.0 ± 7.21 | 4.5 ± 6.83 |
Collected over Baseline through Week 12. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Ranolazine | — | 0/39 (0%) | 12/39 (30.8%) |
| Placebo | — | 1/41 (2.4%) | 15/41 (36.6%) |
| Event | Ranolazine | Placebo |
|---|---|---|
| Musculoskeletal PainMusculoskeletal and connective tissue disorders | 0/39 | 1/41 |
| Event | Ranolazine | Placebo |
|---|---|---|
| HyperglycaemiaMetabolism and nutrition disorders | 1/39 | 5/41 |
| HypoglycaemiaMetabolism and nutrition disorders | 4/39 | 3/41 |
| DiarrhoeaGastrointestinal disorders | 3/39 | 3/41 |
| NauseaGastrointestinal disorders | 3/39 | 1/41 |
| DizzinessNervous system disorders | 3/39 | 0/41 |
| HeadacheNervous system disorders | 1/39 | 3/41 |
| Abdominal painGastrointestinal disorders | 2/39 | 1/41 |
| InsomniaPsychiatric disorders | 2/39 | 1/41 |
| AstheniaGeneral disorders | 2/39 | 0/41 |
Safety Analysis Set
| Age Continuous(years) | Ranolazine | Placebo | Total |
|---|---|---|---|
| Mean | 58 ± 10.1 | 58 ± 9.1 | 58 ± 9.5 |
| Sex: Female, Male(Participants) | Ranolazine | Placebo | Total |
|---|---|---|---|
| Female | 16 | 16 | 32 |
| Male | 23 | 25 | 48 |
| Ethnicity (NIH/OMB)(Participants) | Ranolazine | Placebo | Total |
|---|---|---|---|
| Hispanic or Latino | 25 | 28 | 53 |
| Not Hispanic or Latino | 14 | 13 | 27 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race/Ethnicity, Customized(participants) | Ranolazine | Placebo | Total |
|---|---|---|---|
| White | 33 | 39 | 72 |
| Black | 5 | 1 | 6 |
| Other | 1 | 1 | 2 |
| Glycosylated hemoglobin (HbA1c)(percent HbA1c in blood) | Ranolazine | Placebo | Total |
|---|---|---|---|
| Mean | 8.41 ± 1.078 | 8.51 ± 1.163 | 8.46 ± 1.117 |
| 2-hour Postprandial Glucose(mg/dL) | Ranolazine | Placebo | Total |
|---|---|---|---|
| Mean | 253.1 ± 57.37 | 271.5 ± 87.67 | 262.5 ± 74.57 |
| Fasting Serum Glucose(mg/dL) | Ranolazine | Placebo | Total |
|---|---|---|---|
| Mean | 153.7 ± 43.05 | 172.7 ± 52.20 | 163.4 ± 48.60 |
The record gives a start of Jun 2010, a primary completion of Nov 2010 and a completion of Nov 2010. It does not say whether these dates are actual or estimated.
Results were first posted in Sep 2013, 2 years 10 months after primary completion. A results delay was requested in Jul 2011.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2013. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ranolazine